Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta-Reference-Cited by-同舟云学术

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta

Published:2016-03 Issue: Volume:430 Page:1-9
ISSN:0022-1759
Container-title:Journal of Immunological Methods
language:en
Short-container-title:Journal of Immunological Methods

Author:

Hermanrud Christina,Ryner Malin,Luft Thomas^ORCID,Jensen Poul Erik,Ingenhoven Kathleen,Rat Dorothea,Deisenhammer Florian,Sørensen Per Soelberg,Pallardy Marc,Sikkema Dan,Bertotti Elisa,Kramer Daniel,Creeke Paul,Fogdell-Hahn Anna

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference22 articles.

1. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta;Bertolotto;J. Immunol. Methods,2007

2. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins;EMA;European Medicines Agency,2008

3. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta;Farrell;Mult. Scler.,2008

4. Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins;FDA;USA Food and Drug Administration,2009

5. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit;Grossberg;J. Interf. Cytokine Res.,2001

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity;Clinical Immunology;2024-10

2. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis;CNS Drugs;2022-05-19

3. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS;BMC Medicine;2020-11-04

4. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium;PLOS Medicine;2020-10-30

5. Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ;Frontiers in Immunology;2020-07-17